AU2019395250A1 - Deutetrabenazine for the treatment of dyskinesia in cerebral palsy - Google Patents

Deutetrabenazine for the treatment of dyskinesia in cerebral palsy Download PDF

Info

Publication number
AU2019395250A1
AU2019395250A1 AU2019395250A AU2019395250A AU2019395250A1 AU 2019395250 A1 AU2019395250 A1 AU 2019395250A1 AU 2019395250 A AU2019395250 A AU 2019395250A AU 2019395250 A AU2019395250 A AU 2019395250A AU 2019395250 A1 AU2019395250 A1 AU 2019395250A1
Authority
AU
Australia
Prior art keywords
patient
baseline
deutetrabenazine
score
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019395250A
Other languages
English (en)
Inventor
Mark Forrest Gordon
Juha-Matti Savola
Frank Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auspex Pharmaceuticals Inc
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of AU2019395250A1 publication Critical patent/AU2019395250A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019395250A 2018-12-13 2019-12-13 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy Abandoned AU2019395250A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779232P 2018-12-13 2018-12-13
US62/779,232 2018-12-13
US201962801450P 2019-02-05 2019-02-05
US62/801,450 2019-02-05
PCT/US2019/066150 WO2020123900A1 (en) 2018-12-13 2019-12-13 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy

Publications (1)

Publication Number Publication Date
AU2019395250A1 true AU2019395250A1 (en) 2021-07-29

Family

ID=69173404

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019395250A Abandoned AU2019395250A1 (en) 2018-12-13 2019-12-13 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy

Country Status (15)

Country Link
US (3) US11324732B2 (https=)
EP (1) EP3893876A1 (https=)
JP (1) JP2022519007A (https=)
KR (1) KR20210114946A (https=)
CN (1) CN113395966A (https=)
AU (1) AU2019395250A1 (https=)
BR (1) BR112021011386A2 (https=)
CA (1) CA3123393A1 (https=)
CL (1) CL2021001554A1 (https=)
IL (1) IL283920A (https=)
MX (1) MX2021007063A (https=)
SG (1) SG11202106344SA (https=)
TW (1) TWI784220B (https=)
WO (1) WO2020123900A1 (https=)
ZA (1) ZA202104786B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI784220B (zh) * 2018-12-13 2022-11-21 美商奧斯拜客斯製藥有限公司 腦性麻痺運動障礙之治療方法
IL307678A (en) * 2021-04-15 2023-12-01 Neurocrine Biosciences Inc Methods of administering certain VMAT2 inhibitors
JP2024514873A (ja) * 2021-04-15 2024-04-03 ニューロクライン バイオサイエンシーズ，インコーポレイテッド デューテトラベナジンおよびｃｙｐ２ｄ６阻害剤の併用投与のための方法
WO2024090922A1 (ko) 2022-10-24 2024-05-02 주식회사 디자인셀 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044981A2 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2015200243B2 (en) * 2009-06-24 2016-09-29 Egalet Ltd Controlled release formulations
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CN104684555A (zh) 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
HRP20221106T1 (hr) * 2015-03-06 2022-11-25 Auspex Pharmaceuticals, Inc. Postupci liječenja abnormalnih nevoljnih poremećaja pokreta
UA127052C2 (uk) * 2017-03-15 2023-03-29 Оспекс Фармасьютікалс, Інк. Аналоги деутетрабеназину, їхнє отримання та застосування
TWI784220B (zh) * 2018-12-13 2022-11-21 美商奧斯拜客斯製藥有限公司 腦性麻痺運動障礙之治療方法

Also Published As

Publication number Publication date
CL2021001554A1 (es) 2022-02-11
US20240082225A1 (en) 2024-03-14
TW202034917A (zh) 2020-10-01
SG11202106344SA (en) 2021-07-29
US20220409597A1 (en) 2022-12-29
BR112021011386A2 (pt) 2021-08-31
US20200188371A1 (en) 2020-06-18
TWI784220B (zh) 2022-11-21
KR20210114946A (ko) 2021-09-24
IL283920A (en) 2021-07-29
MX2021007063A (es) 2021-12-10
ZA202104786B (en) 2023-12-20
CN113395966A (zh) 2021-09-14
JP2022519007A (ja) 2022-03-18
EP3893876A1 (en) 2021-10-20
CA3123393A1 (en) 2020-06-18
WO2020123900A1 (en) 2020-06-18
US11324732B2 (en) 2022-05-10

Similar Documents

Publication Publication Date Title
ES2879631T3 (es) Pridopidina para el tratamiento de la enfermedad de Huntington
US20240082225A1 (en) Methods for the treatment of dyskinesia in cerebral palsy
US20230321007A1 (en) Pharmacokinetics of nmda receptor antagonists
US12390456B2 (en) Pridopidine for treating Huntington's disease
CN108135865A (zh) 使用芬氟拉明治疗Lennox-Gastaut综合征的方法
US20250352533A1 (en) Pridopidine for treating huntington's disease
CN113825510A (zh) 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法
JP2009515952A (ja) 制御放出性製剤のクエチアピン
JP2024517937A (ja) Ｎｍｄａ受容体拮抗薬の副作用の低減
WO2024145288A2 (en) Methods of administering r-ketamine
EA044015B1 (ru) Дейтетрабеназин для лечения дискинезии при церебральном параличе
EP4618973A1 (en) Methods of switching neuropsychiatric medications using ulotaront
WO2025257799A1 (en) Methods of treating dravet syndrome
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
Adler et al. Intervention Helps Workers With Depression.
Class et al. Patent application title: PRIDOPIDINE FOR TREATING HUNTINGTON'S DISEASE
CN121013719A (zh) 治疗特发性震颤的方法
BA A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa
Chan et al. Basics of Psychopharmacological Management
HK1255881A1 (zh) 使用芬氟拉明治疗lennox-gastaut综合征的方法
EA039995B1 (ru) Применение придопидина для лечения болезни хантингтона

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted